Apotex, Pfizer Make Peace On Generic Neurontin

Law360, New York (February 26, 2008, 12:00 AM EST) -- Apotex Corp. and Pfizer Inc. have settled all outstanding patent infringement and antitrust litigation over Pfizer's blockbuster epilepsy drug, Neurontin, which had earned the company more than $2 billion a year.

Having resolved almost a decade of dispute, Apotex is now free to continue marketing and selling the generic gabapentin capsules and tablets it first launched at risk in April 2005, an Apotex statement said Monday.

The terms and conditions of the settlement are confidential.

“We are pleased that we have been able to resolve this...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.